Scarica l'app Stockscreener
0.3201
1.05%
-0.0037
Applied Therapeutics Inc Borsa (APLT) Ultime notizie
Applied Therapeutics promotes two executives to leadership roles By Investing.com - Investing.com South Africa
Applied Therapeutics Announces New Chief Medical Officer - TipRanks
APLT Announces Key Executive Promotions | APLT Stock News - GuruFocus
Applied Therapeutics Promotes Evan Bailey to Chief Medical Officer - MarketScreener
Applied Therapeutics Announces Key Leadership Appointments | APLT Stock News - GuruFocus
Applied Therapeutics promotes two executives to leadership roles - Investing.com
Applied Therapeutics Announces Key Leadership Appointments - GlobeNewswire
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Makes New Investment in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
California State Teachers Retirement System Purchases 64,316 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics holds annual stockholders meeting By Investing.com - Investing.com Canada
Applied Therapeutics Elects New Director at Annual Meeting - TipRanks
Applied Therapeutics holds annual stockholders meeting - Investing.com
Two Sigma Investments LP Buys New Shares in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics, Inc. (NASDAQ:APLT) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Set Applied Therapeutics, Inc. (NASDAQ:APLT) Target Price at $6.10 - Defense World
Wellington Management Group LLP Boosts Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Applied Therapeutics, Inc. (NASDAQ:APLT) Shares Acquired by Millennium Management LLC - MarketBeat
Shareholder Rights Advocates at Levi & Korsinsky Investigate Applied Therapeutics, Inc. (APLT) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Applied Therapeutics, Inc. (NASDAQ:APLT) Short Interest Update - MarketBeat
Millennium Management LLC Boosts Holdings in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Class Action Filed Against Applied Therapeutics, Inc. (APLT)February 18, 2025 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. LawsuitAPLT - ACCESS Newswire
Shareholders of Applied Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
BNP Paribas Financial Markets Grows Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Janus Henderson Group PLC Sells 10,505,737 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Columbia Trustee Got Sued for Securities Fraud — Then Left Her Pharma Firm Under a Cloud - The Intercept
Janus Henderson Group PLC Decreases Stake in Applied Therapeutics, Inc. (NASDAQ:APLT) - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Investors to Inquire about Securities Investigation - ACCESS Newswire
Price T Rowe Associates Inc. MD Sells 986,108 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
William Blair Brokers Increase Earnings Estimates for APLT - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Vestal Point Capital LP Acquires 10,355,000 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT) - MarketBeat
Applied Therapeutics (NASDAQ:APLT) Stock Rating Upgraded by Wall Street Zen - Defense World
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Applied Therapeutics Inc (APLT): An Important Analyst Insights - Stocksregister
Applied Therapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 18, 2025 to Discuss Your Rights – APLT - ACCESS Newswire
Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug - MSN
Applied Therapeutics’ Rare Disease Treatment Flunks in Late-Stage Trial - NewsBreak: Local News & Alerts
New top-line data from Phase II/III trial of govorestat in CMT-SORD - The Pharma Letter
Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug By Stocktwits - Investing.com India
Applied Therapeutics Presents Full 12-Month Clinical Results and - GuruFocus
APLT Shares Results from INSPIRE Trial on Govorestat at Peripher - GuruFocus
APLT Shares Results from INSPIRE Trial on Govorestat at Peripheral Nerve Society Meeting | APLT Stock News - GuruFocus
Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting - The Manila Times
Applied Therapeutics Presents Full 12-Month Clinical - GlobeNewswire
Breakthrough in CMT Treatment: New Clinical Data Shows First-Ever Disease Progression Slowing in 24-Month Study - Stock Titan
Here's Why Amazon Is a Brilliant Buy Now (Hint: It's Not E-Commerce) - The Globe and Mail
Massive News for Apple Stock Investors! - The Globe and Mail
0.37%
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):